Bayer’s August Pivot: Earnings, a Rescheduled Hearing, and Rating Reality Check

Bayer shares fell 4.34% last week as Fitch maintained a negative outlook and the Roundup fairness hearing was postponed, offsetting earlier Supreme Court gains.

Bayer’s stock has surged 72.29% over the past twelve months, a rally built largely on the Supreme Court’s landmark 7-2 decision that narrowed the path for state-level cancer warning claims tied to glyphosate. Yet in the past week, the shares slid 4.34% to close Friday at €48.06 – still up 0.97% on the day – as investors digested two sobering developments: a Fitch Ratings decision that kept the company on a negative outlook, and a one-month postponement of the critical “fairness hearing” for the $7.25 billion Roundup class-action settlement.

The hearing, originally slated for early July in a Missouri court, has been pushed to August 19. Bayer disclosed the delay on July 18, noting that the final approval of the settlement remains a pivotal step toward resolving the bulk of outstanding U.S. glyphosate lawsuits. The shift in calendar comes even as the legal environment broadly improves, but it injects fresh uncertainty into a stock that had hit a 52-week high of €53.86 on July 3 before retreating 10.77%.

Fitch’s Caution Underscores Balance-Sheet Pressure

On July 13, Fitch affirmed Bayer’s long-term issuer default rating at BBB but left the outlook at negative. The agency pointed to “persistent operational uncertainties” and, crucially, highlighted the company’s high net debt and ongoing free cash flow drains. This conservative stance arrives despite the Supreme Court relief, signalling that the rating agency views Bayer’s financial health as a separate, unresolved challenge. The company entered a quiet period on July 15, meaning management will not comment publicly on current trading until the half-year results are released on August 4.

In a bid to shore up its balance sheet, Bayer closed a $5.0 billion USD bond placement on July 17 to refinance existing debt. Just a week earlier, on July 10, it secured €3.0 billion in equity from Apollo Global Management, granting funds managed by Apollo a minority stake in a new entity housing Bayer’s long-acting reversible contraceptive business. These capital moves helped ease near-term financing pressure, but Fitch’s position suggests they have not fully allayed structural concerns.

Analysts Split on Sustainability of Rally

The analyst community reflects the tension between legal progress and financial drag. Barclays raised its price target on July 14 from €50 to €60, maintaining an Overweight rating, citing the Supreme Court victory. JPMorgan reaffirmed Overweight with a €50 target on July 17. Berenberg moved its target from €40.50 to €55 on July 7 but kept a Hold rating, noting that the improved legal picture boosts the option for a future corporate breakup.

On the more cautious side, Jefferies reiterated a Hold on July 13 with a €46 price target – below the current share price – pointing to high debt and persistent cash outflows. ODDO BHF, while constructive, sees Bayer’s consolidation of its U.S. glyphosate business into a new unit called Ruveon as a preparatory step for a potential separation or sale, but acknowledges that the entity remains fully owned. UBS, with a Buy rating and €52 target, sees the August 19 hearing as a potential catalyst.

Growth Projects Beyond the Courtroom

Away from litigation, Bayer continues to lay groundwork for long-term expansion. The pharmaceutical division is seeing strong momentum from Nubeqa, up 57.1%, and Kerendia, up 84.2%, driven by volume growth in the U.S., Europe, and China – partially offsetting the decline of Xarelto as patent protection lapses. In agriculture, Bayer announced an exclusive licensing deal with French seed firm RAGT on July 15 to develop hybrid wheat, targeting a market launch in both Europe and North America by the early 2030s. The company projects annual revenues of up to €1 billion from the segment by the mid-2040s.

Meanwhile, asset manager Amundi crossed the 3% voting rights threshold at Bayer on July 14, now indirectly holding 3.09% or 30,375,174 voting rights – a signal of institutional interest that adds another layer of scrutiny.

What’s Next: The August Calendar Looms

The next two data points will dominate investor attention. On August 4, Bayer reports its half-year financials, ending the quiet period. The market will be laser-focused on net debt reduction and free cash flow stabilization – metrics that could counter Fitch’s skepticism. A day after that report, the stock enters a period of elevated uncertainty ahead of the August 19 settlement hearing.

Technically, the stock’s RSI of 59.3 signals neither overbought nor oversold, leaving room for movement in either direction. The 30-day annualized volatility stands at 62.01%, reflecting the market’s expectation of wide swings. If the earnings confirm improving leverage and the hearing proceeds smoothly, the rally could regain momentum. But if the balance sheet disappoints or the courtroom setback spawns new delays, the shares may test the 50-day moving average at €41.25 – a level that would represent a further 14% drop from Friday’s close.